Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis and nasal polyps in adults and children, reducing inflammation and nasal congestion. GNH USA supplies Nasonex as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasonex is a nasal corticosteroid that acts on inflammatory processes of the upper airway. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. - Nasal polyps: reduces polyp size and improves nasal airflow. - Seasonal allergic rhinitis: controls symptoms triggered by seasonal allergens.

Nasonex may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleeds) - Throat irritation or dryness - Cough - Altered taste or smell

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes or cataract formation - Adrenal suppression with prolonged high‑dose use - Opportunistic fungal infection of the nasal cavity - Persistent or worsening nasal bleeding

Before using Nasonex, consider the following safety measures. - Prescription use only: follow the prescriber's instructions. - Age restriction: not recommended for children under the approved age without medical guidance. - Recent nasal surgery or trauma: avoid use until healed. - Monitor for signs of infection or worsening symptoms. - Caution in patients with glaucoma, cataracts, or diabetes. - Store at room temperature: keep in the original package, protect from moisture and direct sunlight.

Nasonex can interact with other medications that affect corticosteroid activity or metabolism.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise mometasone exposure. - Live vaccines: potential reduction in vaccine efficacy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure. - Antifungal azoles used chronically: monitor for local immunosuppression.